Analysts Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Price Target at $4.73

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned a consensus recommendation of “Hold” from the fourteen analysts that are currently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $4.7292.

A number of research analysts recently commented on the company. Citigroup dropped their price target on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. JPMorgan Chase & Co. reduced their price target on shares of GoodRx from $6.00 to $5.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Barclays began coverage on shares of GoodRx in a research note on Monday, December 8th. They issued an “underweight” rating and a $3.00 price objective on the stock. Mizuho cut their target price on GoodRx from $5.00 to $4.00 and set a “neutral” rating for the company in a research note on Thursday, November 6th. Finally, UBS Group reiterated a “reduce” rating on shares of GoodRx in a research note on Monday, January 5th.

Institutional Trading of GoodRx

Hedge funds and other institutional investors have recently modified their holdings of the stock. Quarry LP acquired a new stake in shares of GoodRx during the third quarter valued at about $33,000. Cetera Investment Advisers bought a new stake in GoodRx in the second quarter worth approximately $50,000. Boothbay Fund Management LLC acquired a new position in shares of GoodRx during the 3rd quarter valued at $43,000. Shay Capital LLC acquired a new position in shares of GoodRx during the third quarter valued at about $47,000. Finally, Walled Lake Planning & Wealth Management LLC bought a new position in GoodRx in the second quarter worth approximately $55,000. Institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

Shares of NASDAQ:GDRX opened at $2.34 on Monday. GoodRx has a 12-month low of $2.27 and a 12-month high of $5.81. The company’s 50 day moving average price is $2.72 and its two-hundred day moving average price is $3.61. The firm has a market cap of $794.27 million, a PE ratio of 26.00, a PEG ratio of 0.89 and a beta of 1.45. The company has a quick ratio of 3.11, a current ratio of 3.11 and a debt-to-equity ratio of 0.81.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $196.03 million during the quarter, compared to the consensus estimate of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. The company’s quarterly revenue was up .4% on a year-over-year basis. During the same quarter last year, the firm posted $0.08 earnings per share. Equities research analysts predict that GoodRx will post 0.13 earnings per share for the current year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.